Browsing by Author "Mannu Kumar Gond"

Now showing 1 - 4 of 4

Cd(II) complexes derived from thiazoline, hydrazide and carbodithioate ligands: synthesis, crystal structures and electrochemical sensing of uric acid
(John Wiley and Sons Ltd, 2023) Shubham Jaiswal; Shivendra Kumar Pandey; Jyoti Prajapati; Suryansh Chandra; Mannu Kumar Gond; Manoj Kumar Bharty; Ida Tiwari; Ray J. Butcher
Three novel Cd(II) metal complexes 1–3 have been synthesized with different derivatives of thiazoline, hydrazide and carbodithioate. These metal complexes are abbreviated as [Cd (tht)2]n, [Cd (Hpph)2]n and [Cd (mpps)2]n along with their respective ligands Htht, H2pph and mpps. The developed metal complexes are characterized using X-ray diffraction (XRD) data and other spectroscopic techniques (Infrared [IR], nuclear magnetic resonance [NMR], ultraviolet–visible [UV–vis] and fluorescence). The polymeric nature of these cadmium complexes have been ascertained by single XRD data. Several significant interactions were also revealed, which aid in the stabilization of these complexes' supramolecular architecture. Comparing complex 2 with complexes 1 and 3, the absorption spectra of complex 2 exhibits a greater λmax. On comparing the fluorescence study of these complexes, complex 2 has a higher fluorescence than complexes 1 and 3. The cyclic voltammetry (CV) approach was employed to detect the electrochemical behaviour of these complexes, as well as the sensing of uric acid (UA) by these complexes via modified glassy carbon electrodes (GCEs). According to the conclusions received by CV study, the modified electrode containing complex 3 has admirable UA electro catalytic activity. This UA electrochemical sensing device offers a low detection limit (0.3 μM), fine linear ranges (30–1500 μM), reasonable sensitivity, and a fast reaction time. © 2023 John Wiley & Sons Ltd.
Cobalt (III) complex exerts anti-cancer effects on T cell lymphoma through induction of cell cycle arrest and promotion of apoptosis
(Springer Science and Business Media Deutschland GmbH, 2022) Praveen Kumar Verma; Rishi Kant Singh; Sandeep Kumar; Alok Shukla; Sanjay Kumar; Mannu Kumar Gond; Manoj Kumar Bharty; Arbind Acharya
Purpose: Cobalt-based compounds are emerging as a non-platinum-based anti-cancer effective therapeutic agent. However, there is a limited study regarding the therapeutic efficacy of Cobalt-based drugs against Non-Hodgkin’s Lymphoma (NHLs) such as T cell lymphoma. Therefore, in the present study we investigated the anti-tumor role of cobalt(III) complex [Co(ptsm)NH3(o-phen)]·CH3OH on Dalton’s Lymphoma (DL) cells. Materials and methods: Cytotoxicity of the cobalt complex was estimated by MTT assay. Analysis of mitochondrial membrane potential, cell cycle and Reactive oxygen species (ROS) generation, and Annexin V/PI staining was done by Flow cytometry, while AO/EtBr staining by fluorescence microscopy in cobalt complex treated DL cell. Expression of cell cycle and apoptosis regulatory protein was analyzed by Western blotting. In addition, in vivo study of the cobalt complex was evaluated in well-established DL bearing mice by monitoring physiological parameters and mean survival time. Results: Our study showed that cobalt complex triggered apoptosis and induced cell cycle arrest in DL cells. Furthermore, this also decreased mitochondrial membrane potential and increased intracellular ROS generation in cancer cells. In addition, changed expression of cell cycle and apoptosis regulatory protein was found with enhanced activity of caspase-3 and 9 in the treated cells. Additionally, administration of cobalt complex showed a significant increase in the survivability of tumor-bearing host, which was accomplished by decreasing physiological parameters. Conclusion: Taken together, these data revealed anti-tumor potential of cobalt complex against DL cells through cell cycle arrest and mitochondrial-dependent apoptosis. Henceforth, cobalt-based drugs could be a new generation therapeutic drug to treat hematological malignancies. Graphical abstract: [Figure not available: see fulltext.]. © 2022, Springer Nature Switzerland AG.
Mitochondrial pathway mediated apoptosis and cell cycle arrest triggered by cobalt(III) complex in Dalton’s lymphoma cells
(Open Science Publishers LLP Inc., 2021) Praveen Kumar Verma; Mannu Kumar Gond; Manoj Kumar Bharty; Arbind Acharya
Cancer is a group of diseases which evolves from uncontrolled growth of abnormal cells. It has become the second leading cause of death worldwide. Many platinum-based compounds like cisplatin and carboplatin are widely used as a therapeutic approach against cancer, but patients are resistant to these therapeutic agents with life-threatening side effects. In this study, we used a non-platinum-based compound, i.e. cobalt complex, on the Dalton’s lymphoma cells (DL cells). It is a tumor model of murine T-cell lymphoma of thymic genesis, which is very aggressive. The present study was focused on evaluating the anticancer efficacy of cobalt complex on DL cells. The IC50 value of cobalt complex was found to be 80 ±3.21 µM in DL cells’. In addition, cobalt complex promoted condensed nuclei, G1 phase arrest, and induced early and late apoptotic cells. Additionally, flow cytometry examination showed a significant loss in mitochondrial membrane potential and induction of reactive oxygen species after treatment. Furthermore, Western blot revealed the increased p53, cyt-c, Bax protein, and decreased Bcl2 protein level in treated DL cells. These results verified the anticancer properties of cobalt(III) complex against DL cells and propose an alternative therapeutic drug in cancer treatment. © 2021. Praveen Kumar Verma et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Synthesis, structural characterisation, and anticancer potential of mono and dinuclear Pd(ii) complexes of N-(2-pyridyl)thiourea
(Royal Society of Chemistry, 2024) Shivendra Kumar Pandey; Sandeep Kumar; Swati Singh; Anand Kumar Patel; Mannu Kumar Gond; Arbind Acharya; Manoj Kumar Bharty
Cancer is a prominent global cause of mortality. Palladium complexes have the potential to serve as effective anticancer and pharmacological agents, offering a viable alternative to platinum medications. This work focused on the development of a new thiolato-bridged dinuclear [Pd(M3MPyThU)Cl]2 and mononuclear palladium [Pd(M3MPyThU)2] complexes containing 1-methyl-3-(3-methylpyridin-2-yl) thiourea (HM3MPyThU) ligand. The prepared ligand and complexes have been fully characterised by various spectroscopic and single-crystal crystallographic data. The ligand and complexes were further examined for their anticancer activities against the HT-29 (human colon) and MCF-7 (human breast) cancer cells along with the standard drug cisplatin, and the outcome suggests that tested compounds have a better cytotoxic response against HT-29 cells. The order of anticancer activity was found as [Pd(M3MPyThU)Cl]2 > cisplatin > [Pd(M3MPyThU)2] > HM3MPyThU. The complex [Pd(M3MPyThU)Cl]2 demonstrated potent cytotoxic effects against HT-29 cells with an IC50 value of 10 ± 3.3 μM. The comparison of the anticancer activity of the described complexes with previous reports on HT-29 cells suggests that the described complexes have better anticancer activity than previously reported complexes. Further assays were performed for [Pd(M3MPyThU)Cl]2 to gain insights into the mechanism of cell death and found that reduced mitochondrial membrane potential and increased ROS production, highlighting mitochondrial-dependent apoptosis as the major mechanism for tumour cell death. Additionally, [Pd(M3MPyThU)Cl]2 was found to be more selective compared to cisplatin since it exhibited decreased toxicity towards healthy cells (HEK-293). © 2025 The Royal Society of Chemistry.